Autoimmune Skin Disease Study Unit
Lupus Erythematosus
- A Phase 2b Dose Ranging Study to Evaluate the Efficacy and Safety of Rozibafusp Alfa (AMG 570) in Subjects With Active Systemic Lupus Erythematosus (SLE) With Inadequate Response to Standard of Care (SOC) Therapy
- Optimization of Clinical Trial Design in Cutaneous Lupus: NIH funded study to collect data on natural disease activity and outcomes
Dermatomyositis
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis
- A Phase 2 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of PF-06823859 in Adult Subjects with Dermatomyositis
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) in Adults with Dermatomyositis (DM)
Pemphigus Vulgaris
- A Randomized, Double-Blinded, Placebo-Controlled Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Pemphigus (Vulgaris or Foliaceus) (ADDRESS)
Bullous Pemphigoid
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients with Bullous Pemphigoid.
To refer a patient or to learn more about the program and participation in a clinical trial, contact us at 215-615-2940. Pharmaceutical and other clinical and research professionals may contact Dr. Victoria Werth directly at werth@pennmedicine.upenn.edu.